Royalty Pharma is less exposed to MFN drug pricing risks, offering downside protection in a volatile policy environment. See ...

A recent White House executive order could make it harder for millions of Americans to access their lifesaving medications.

FDA’s public guidance continues to warn that, “under most circumstances,” importing drugs for personal use is unlawful, ...

While platform players are going super-wide in their offering, some legal AI startups are going the other way and drilling ...

CEO of the National Infusion Center Association argues against a drug price control policy known as “most favored nation.” ...

The MFN EO is designed to halt what the administration calls “global freeloading” — where other developed countries benefit from U.S.-funded drug innovation at significantly lower costs.

By Melanie Whittington President Trump recently signed a new executive order advancing a “most favored nation” (MFN) approach to drug pricing. The policy would link U.S. prices for certain medicines ...

With uncertainties clouding the outcome, Gokaldas Exports MD Sivaramakrishnan Ganapathi sees status quo as the base case, ...

Proposed drug price controls and NIH funding cuts could stall U.S. medical innovation and hinder the development of ...

Orforglipron is an oral drug from Eli Lilly that’s in trial stage. The New York Times reports that in a trial of over 500 ...

President Donald Trump issued an executive order reviving his controversial “Most Favored Nation” (MFN) drug pricing ...